J&J finalizes $25M settlement, laying Remicade antitrust allegations to rest
A Pennsylvania federal judge on Wednesday cemented a $25 million settlement in a class action suit alleging Johnson & Johnson blocked biosimilar competition to its immunosuppressive drug Remicade.
First approved in 1998 for Crohn’s disease, Remicade (a TNF inhibitor biologic also known as infliximab) has since been cleared in a slate of other immune-mediated conditions, including ulcerative colitis, psoriatic arthritis and rheumatoid arthritis. However, the yearly cost for some patients reaches $26,000, according to a complaint updated in 2018.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.